Research Paper Volume 12, Issue 11 pp 10827—10843

High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations

Figure 2. Correlation of MUC16 mutations with tumor mutational load in 2 cohorts. (A, B) Mutation burden of melanoma samples with and without MUC16 mutation (left: TCGA; right: ICGC). (C, D) Multivariate logistic regression models were conducted to explore association of MUC16 mutations with TML (left: TCGA; right: ICGC).